MDM2 and neoplasm: To address these additional resistance mechanisms, MDM2 inhibitors have been used in conjunction with immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-PD-L1 therapies, to enhance anti-tumor immunity.